Theravance Biopharma
TBPH
119 hedge funds and large institutions have $696M invested in Theravance Biopharma in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 39 reducing their positions, and 21 closing their positions.
709% more call options, than puts
Call options by funds: $13.2M | Put options by funds: $1.63M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
8.28% more ownership
Funds ownership: 83.85% → 92.13% (+8.3%)
7% more capital invested
Capital invested by funds: $648M → $696M (+$48.4M)
0% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 39
3% less funds holding
Funds holding: 123 → 119 (-4)
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$3.28M |
| 2 |
Two Sigma Investments
New York
|
+$3.26M |
| 3 |
BlackRock
New York
|
+$2.35M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.15M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$21M |
| 2 |
NM
Newtyn Management
New York
|
-$11M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.7M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.61M |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
-$3.25M |
TBPH Hedge Fund Activity: Q4 2022 in Review
119 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2022, worth a combined $696M — up 7.5% from $648M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of TBPH and 18 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 39 added.
The largest buyer was Two Sigma Advisers, adding an estimated $3.28M. The largest seller was Baupost Group, cutting an estimated $21M.
- 119 institutional investors held Theravance Biopharma (TBPH) as of Q4 2022, down from 123 in Q3 2022.
- Funds reported $696M of Theravance Biopharma stock for Q4 2022, up 7.5% quarter-over-quarter.
- 18 funds opened new Theravance Biopharma positions in Q4 2022 and 21 closed out, a net change of -3 holders.
- The largest Theravance Biopharma buyer in Q4 2022 was Two Sigma Advisers, an estimated $3.28M added.
- The largest Theravance Biopharma seller in Q4 2022 was Baupost Group, an estimated $21M sold.
Based on aggregated 13F filings for Q4 2022.